Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
Abstract Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational antigen design through to manufacturability and vaccine efficacy of a prefusion‐stabilised spike (S) protein, Sclamp,...
Similar Items
-
Rapid Response Subunit Vaccine Design in the Absence of Structural Information
by: Danushka K. Wijesundara, et al.
Published: (2020-11-01) -
Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
by: Ariel Isaacs, et al.
Published: (2021-01-01) -
Unravelling the convoluted biological roles of Type I interferons (IFN-Is) in infection and immunity: a way forward for therapeutics and vaccine design
by: Danushka Kumara Wijesundara, et al.
Published: (2014-08-01) -
Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse.
by: Naphak Modhiran, et al.
Published: (2010-01-01) -
Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1
by: Danushka K. Wijesundara, et al.
Published: (2017-10-01)